Bekker P - Search Results

1

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P; 20000223 Study Group. Genovese MC, et al. Among authors: bekker p. Arthritis Rheum. 2004 May;50(5):1412-9. doi: 10.1002/art.20221. Arthritis Rheum. 2004. PMID: 15146410 Clinical Trial.

2

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial.

Tak PP, Balanescu A, Tseluyko V, Bojin S, Drescher E, Dairaghi D, Miao S, Marchesin V, Jaen J, Schall TJ, Bekker P. Tak PP, et al. Among authors: bekker p. Ann Rheum Dis. 2013 Mar;72(3):337-44. doi: 10.1136/annrheumdis-2011-201605. Epub 2012 May 15. Ann Rheum Dis. 2013. PMID: 22589376 Clinical Trial.

3

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. de Zeeuw D, et al. Among authors: bekker p. Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9. Lancet Diabetes Endocrinol. 2015. PMID: 26268910 Clinical Trial.

4

Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC. Dairaghi DJ, et al. Among authors: bekker p. Clin Pharmacol Ther. 2011 May;89(5):726-34. doi: 10.1038/clpt.2011.33. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451509 Clinical Trial.

5

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group. Jayne DRW, et al. Among authors: bekker p. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11. J Am Soc Nephrol. 2017. PMID: 28400446 Free PMC article. Clinical Trial.

6

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.

Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group. Keshav S, et al. Among authors: bekker p. PLoS One. 2013;8(3):e60094. doi: 10.1371/journal.pone.0060094. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23527300 Free PMC article. Clinical Trial.

7

Risedronate in Paget's disease: preliminary results of a multicenter study.

Brown JP, Kylstra JW, Bekker PJ, Axelrod DW, Siris ES, Altman RD, Singer FR. Brown JP, et al. Among authors: bekker pj. Semin Arthritis Rheum. 1994 Feb;23(4):272. doi: 10.1016/0049-0172(94)90060-4. Semin Arthritis Rheum. 1994. PMID: 8009253 Clinical Trial. No abstract available.

8

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ. Walters MJ, et al. Among authors: bekker p. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9. doi: 10.1124/jpet.110.169714. Epub 2010 Jul 21. J Pharmacol Exp Ther. 2010. PMID: 20660125

9

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. Miller PD, et al. Among authors: bekker pj. Am J Med. 1999 May;106(5):513-20. doi: 10.1016/s0002-9343(99)00062-5. Am J Med. 1999. PMID: 10335722 Clinical Trial.

10

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.

Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, Johnson TD, Bekker PJ. Brown JP, et al. Among authors: bekker pj. Calcif Tissue Int. 1999 Feb;64(2):93-9. doi: 10.1007/s002239900584. Calcif Tissue Int. 1999. PMID: 9914313 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results